550-551DOI: 10.17235/reed.2020.7529/2020
Original
Psychological disorders and coping strategies in patients with inflammatory bowel disease. Their impact on health-related quality of life
DOI: 10.17235/reed.2023.9935/2023
Letter
Tofacitinib-induced eosinophilia
DOI: 10.17235/reed.2023.9831/2023
Sarcopenia and treatment failure in inflammatory bowel disease: a systematic review and meta-analysis
DOI: 10.17235/reed.2023.9808/2023
Ulcerative colitis overall disease severity index predicts colectomy: a prospective cohort study
DOI: 10.17235/reed.2023.9754/2023
Infliximab-induced psoriasis in an ulcerative colitis patient successfully treated with guselkumab
DOI: 10.17235/reed.2023.9745/2023
Development and validation of a nomogram to predict non-response to 5-aminosalicylic acid in patients with ulcerative colitis
DOI: 10.17235/reed.2023.9703/2023
Extensive involvement of indolent T-cell lymphoma in a patient with ulcerative colitis
DOI: 10.17235/reed.2023.9623/2023
Iatrogenic rectal perforation due to application of topical treatment in a patient with ulcerative colitis: a rare complication
DOI: 10.17235/reed.2023.9599/2023
Long-term clinical outcomes after the discontinuation of anti-TNF agents in patients with inflammatory bowel disease: a meta-analysis
DOI: 10.17235/reed.2023.9537/2023
Fecal immunochemical test for hemoglobin versus fecal calprotectin to monitor endoscopic activity in inflammatory bowel disease
DOI: 10.17235/reed.2023.9536/2023
Severe outbreak of ulcerative colitis and cerebral neoplasia. Difficult management in COVID time
DOI: 10.17235/reed.2023.9527/2023
The HLA-DQA1*05 genotype does not influence the clinical response to ustekinumab and vedolizumab
DOI: 10.17235/reed.2023.9491/2023
Foreign body impaction between diverticula: an uncommon cause of chronic abdominal pain
DOI: 10.17235/reed.2023.9485/2023
Hepatosplenic T-cell lymphoma and inflammatory bowel disease
DOI: 10.17235/reed.2023.9472/2023
Editorial
Relevance of patient-reported outcome measures (PROM) and patient-reported experience measures (PREM) to assess disease status and quality of care in patients with inflammatory bowel disease
DOI: 10.17235/reed.2023.9563/2022
Reply: SARS-CoV-2 vaccination in inflammatory bowel disease patients with different biological agents
DOI: 10.17235/reed.2023.9438/2022
Henoch-Schönlein purpura masquerading as Crohn’s disease flare
DOI: 10.17235/reed.2022.9414/2022
SARS-CoV-2 vaccination in inflammatory bowel disease patients with different biological agents: correspondence
DOI: 10.17235/reed.2023.9347/2022
Prediagnosis of soft tissue infection that was finally diagnosed as pyoderma gangrenosum of ulcerative colitis
DOI: 10.17235/reed.2022.9332/2022
Perianal Paget’s disease
DOI: 10.17235/reed.2022.9304/2022
Impact of SARS-CoV-2 vaccination in inflammatory bowel disease patients with different biological agents: a systematic review and meta-analysis
DOI: 10.17235/reed.2022.9264/2022
A rare case of ulcerative colitis following Bacillus Calmette-Guérin therapy
DOI: 10.17235/reed.2022.9191/2022
Ulcerative colitis complicated by autoimmune hepatitis-primary biliary cholangitis-primary sclerosing cholangitis overlap syndrome
DOI: 10.17235/reed.2022.9183/2022
Chinese dragon sign of ulcerative colitis
DOI: 10.17235/reed.2022.9154/2022
Crohn’s disease induced by ocrelizumab in a patient with multiple sclerosis
DOI: 10.17235/reed.2022.9152/2022
Digestive Diseases Image
A rare endoscopic pattern in a patient with gastroesophageal reflux disease
DOI: 10.17235/reed.2022.9124/2022
Pyoderma gangrenosum in ulcerative colitis - An exuberant and painful complication
DOI: 10.17235/reed.2022.9120/2022
Serologic response to COVID-19 vaccines in patients with inflammatory bowel disease: a prospective study
DOI: 10.17235/reed.2022.9101/2022
Ulcerative colitis exacerbated by strongyloidiasis
DOI: 10.17235/reed.2022.9044/2022
Hemostasis of a bleeding inverted colonic diverticulum
DOI: 10.17235/reed.2022.9019/2022
Review
“Out of the box” new therapeutic strategies for Crohn´s disease: moving beyond biologics
DOI: 10.17235/reed.2022.9010/2022
The neutrophil-lymphocyte ratio as a predictor of steroid response in patients with severe ulcerative colitis: a retrospective cohort study
DOI: 10.17235/reed.2022.9006/2022
Dual biologic therapy for severe ulcerative colitis, concomitant extraintestinal manifestations and an orbital osteoma: a successful treatment
DOI: 10.17235/reed.2022.8964/2022
A rare case of an intestinal ulcer: AIDS and amebic colitis in a homosexual man with ulcerative colitis
DOI: 10.17235/reed.2022.8903/2022
Efficacy and safety of fecal microbiota transplant for recurrent Clostridium difficile infection in inflammatory bowel disease: a systematic review and meta-analysis
DOI: 10.17235/reed.2022.8814/2022
One appendix too many: a severe IBD-U case in remission after appendectomy
DOI: 10.17235/reed.2022.8809/2022
Impact of proactive therapeutic drug monitoring of infliximab during the induction phase in IBD patients. A Bayesian approach
DOI: 10.17235/reed.2022.8781/2022
Combined aortic mural thrombi and limb ischemia in inflammatory bowel disease – A rare vascular manifestation
DOI: 10.17235/reed.2022.8774/2022
Health-related quality of life decline in clinically stable inflammatory bowel disease patients during the COVID-19 outbreak
DOI: 10.17235/reed.2022.8668/2022
Mesalazine induced interstitial pneumonitis in the COVID era
DOI: 10.17235/reed.2022.8635/2021
Inflammatory bowel disease new-onset during secukinumab therapy: real-world data from a tertiary center
DOI: 10.17235/reed.2021.8397/2021
Efficacy and safety of tofacitinib in the treatment of ulcerative colitis: real-life experience in Andalusia
DOI: 10.17235/reed.2022.8380/2021
Anal neoplasia and perianal Crohn’s disease: myth or reality?
DOI: 10.17235/reed.2021.8317/2021
Apoptotic colopathy as a manifestation of Good’s syndrome
DOI: 10.17235/reed.2021.8297/2021
Radon exposure and inflammatory bowel disease in a radon prone area
DOI: 10.17235/reed.2021.8239/2021
Comparison of satisfaction degree of patients treated at the Inflammatory Bowel Disease Unit (IBDU) of Hospital Universitario 12 de Octubre between previous face-to-face care and telephone care during the COVID-19 pandemic
DOI: 10.17235/reed.2021.8185/2021
Adherence improvement in patients with ulcerative colitis: a multidisciplinary consensus document
DOI: 10.17235/reed.2021.8130/2021
Incidence of inflammatory bowel disease and phenotype at diagnosis in 2011: results of the Epi-IBD 2011 study in the Vigo area
DOI: 10.17235/reed.2021.8003/2021
ABP 501 (adalimumab-atto) in the treatment of inflammatory bowel disease: an example of evidence-based extrapolation
DOI: 10.17235/reed.2021.7921/2021
Impact of Epstein-Barr virus infection on inflammatory bowel disease (IBD) clinical outcomes
DOI: 10.17235/reed.2021.7915/2021
Influence of the onset of the SARS-CoV-2 pandemic on the diagnosis and treatment of ulcerative colitis
DOI: 10.17235/reed.2021.7768/2020
The COVID-19 pandemic shows us in which way the care of patients with inflammatory bowel disease should move
DOI: 10.17235/reed.2021.7765/2020
Usefulness of peripheral blood monocyte count to predict relapse in patients with inflammatory bowel disease: a prospective longitudinal cohort study
DOI: 10.17235/reed.2021.7683/2020
Biosimilar infliximab CPT-13 for inflammatory bowel disease in a real clinical setting: pharmacokinetic outcomes, immunogenicity, and drug survival
DOI: 10.17235/reed.2021.7638/2020
Thiopurine adherence: a high prevalence with low impact on UC outcomes
DOI: 10.17235/reed.2021.7630/2020
Adherence to intravenous biological treatment in inflammatory bowel disease patients during the COVID-19 pandemic
DOI: 10.17235/reed.2020.7562/2020
Consequences and management of COVID-19 on the care activity of an Inflammatory Bowel Disease Unit
DOI: 10.17235/reed.2020.7543/2020
The use of contrast-enhanced ultrasound for chronic inflammatory bowel disease
DOI: 10.17235/reed.2020.7499/2020
Views of patients with inflammatory bowel disease during the COVID-19 pandemic: ACCU survey results
DOI: 10.17235/reed.2020.7472/2020
Intestinal obstruction secondary to Crohn-like disease in common variable immu-nodeficiency
DOI: 10.17235/reed.2020.7440/2020
Prevalence of pyoderma gangrenosum and Sweet´s syndrome in inflammatory bowel disease at a tertiary healthcare center
DOI: 10.17235/reed.2020.7431/2020
Evaluation of epicardial adipose tissue and carotid intima-media thickness as a marker of atherosclerosis in patients with inflammatory bowel disease
DOI: 10.17235/reed.2020.7394/2020
Autoimmune hepatitis, primary sclerosing cholangitis, and inflammatory bowel disease. Sequential overlap syndrome: a twist to the mosaic of autoimmunity
DOI: 10.17235/reed.2020.7512/2020
Inflammatory bowel disease and solid organ transplantation
DOI: 10.17235/reed.2020.7361/2020
Ustekinumab in Crohn's disease: real-world outcomes and predictors of response
DOI: 10.17235/reed.2020.7352/2020
Effectiveness and safety of switching to adalimumab biosimilar ABP 501 in Crohn’s disease: the extrapolation concept
DOI: 10.17235/reed.2020.7253/2020
Prevalence and factors associated with poor sleep quality in inflammatory bowel disease outpatients
DOI: 10.17235/reed.2020.7202/2020
Author´s answer to: “Effect of adacolumn® in ulcerative colitis with COVID-19”
DOI: 10.17235/reed.2020.7188/2020
The effect of Adacolumn® on ulcerative colitis with COVID-19
DOI: 10.17235/reed.2020.7156/2020
COVID-19 and the digestive system: protection and management during the SARS-CoV-2 pandemic
DOI: 10.17235/reed.2020.7128/2020
Vitamin D and inflammatory bowel disease: what do we know so far?
DOI: 10.17235/reed.2020.7061/2020
Glasgow prognostic score is a predictive index for postoperative infectious complications after total proctocolectomy in ulcerative colitis patients
DOI: 10.17235/reed.2020.7047/2020
Sweet syndrome in severe ulcerative flare
DOI: 10.17235/reed.2020.6995/2020
Autoimmune sequential overlap syndrome (autoimmune hepatitis/primary sclerosing cholangitis) and inflammatory bowel disease: three clinical cases
DOI: 10.17235/reed.2020.6938/2020
Gastrointestinal tuberculosis, the great simulator. From inflammatory disease to a tumor
DOI: 10.17235/reed.2020.6934/2020
Usefulness of population pharmacokinetics to optimize the dosage regimen of infliximab in inflammatory bowel disease patients
DOI: 10.17235/reed.2020.6857/2020
Meta-analysis of protein intake on the effect of Crohn’s disease and ulcerative colitis
DOI: 10.17235/reed.2020.6851/2019
Comparison of original and biosimilar infliximab (CTP-13) in biologic-naïve patients with Crohn’s disease and ulcerative colitis: a retrospective, multicenter real-life study in Spain
DOI: 10.17235/reed.2020.6847/2019
Index of the Mayo Endoscopy and Ulcerative Colitis Endoscopy Index of Severity: are they equally valid?
DOI: 10.17235/reed.2020.6832/2019
Vedolizumab-associated psoriasis: until where does gut selectivity go?
DOI: 10.17235/reed.2020.6817/2019
An acute episode of inflammatory bowel disease vs a rare manifestation of an Epstein-Barr virus-positive mucocutaneous ulcer. Case report
DOI: 10.17235/reed.2020.6737/2019
Is celiac disease really associated with inflammatory bowel disease?
DOI: 10.17235/reed.2019.6779/2019
Effectiveness and safety of adalimumab biosimilar ABP 501 in Crohn’s disease: an observational study
DOI: 10.17235/reed.2020.6693/2019
Predictive factors of clinical response to treatment with anti-TNF agents in ulcerative colitis: what have we learned from our patients?
DOI: 10.17235/reed.2020.6688/2019
Association between autoimmune pancreatitis and ulcerative colitis: a report of 12 patients
DOI: 10.17235/reed.2020.6677/2019
Intra-abdominal desmoid tumor and chronic inflammatory bowel disease. An uncommon scenario
DOI: 10.17235/reed.2020.6648/2019
Quality of care through the eyes of the patient in a Spanish inflammatory bowel disease unit
DOI: 10.17235/reed.2020.6620/2019
Usefulness of therapeutic drug monitoring of infliximab during the induction period in patients with inflammatory bowel disease
DOI: 10.17235/reed.2020.6618/2019
Diet as an environmental trigger in inflammatory bowel disease: a retrospective comparative study in two European cohorts
DOI: 10.17235/reed.2020.6552/2019
Megacolon in inflammatory bowel disease: response to infliximab
DOI: 10.17235/reed.2020.6394/2019
Vedolizumab for treatment of chronic refractory pouchitis: a systematic review with pool analysis
DOI: 10.17235/reed.2019.6336/2019
Status of transition care in inflammatory bowel disease in Spain. Different medical perspectives
DOI: 10.17235/reed.2019.6310/2019
Development and validation of the QUECOMIICAT questionnaire: a tool to assess disease-related knowledge in patients with inflammatory bowel disease
DOI: 10.17235/reed.2019.6298/2019
Differences in the need for adalimumab dose optimization between Crohn’s disease and ulcerative colitis
DOI: 10.17235/reed.2019.6148/2018
Diet in the etiology of inflammatory bowel disease
DOI: 10.17235/reed.2018.6119/2018
The main determinants of disability in IBD and its relationship to optimism
DOI: 10.17235/reed.2019.6033/2018
Treat to target in inflammatory bowel disease: a survey of treatment strategies amongst Portuguese doctors
DOI: 10.17235/reed.2019.6029/2018
A rare lymphoproliferative disorder associated with immunomodulating therapy in Crohn’s disease
DOI: 10.17235/reed.2019.5990/2018
Case Report
Leukocytoclastic vasculitis after vaccination in a patient with inflammatory bowel disease
DOI: 10.17235/reed.2019.5963/2018
Serrated Lesions in patients with Inflammatory Bowel Disease.
DOI: 10.17235/reed.2019.5910/2018
The onset of ulcerative colitis during treatment with secukinumab: can anti-IL-17A be a trigger for inflammatory bowel disease?
DOI: 10.17235/reed.2019.5841/2018
The use of serum calprotectin as a biomarker for inflammatory activity in inflammatory bowel disease
DOI: 10.17235/reed.2019.5797/2018
Vitamin D deficiency in outpatients with inflammatory bowel disease: prevalence and association with clinical-biological activity
DOI: 10.17235/reed.2018.5714/2018
Validation of a population pharmacokinetic model of adalimumab in a cohort of patients with inflammatory bowel disease
DOI: 10.17235/reed.2019.5600/2018
The association between de novo inflammatory bowel disease and celiac disease
DOI: 10.17235/reed.2019.5535/2018
Online social networks and inflammatory bowel disease
DOI: 10.17235/reed.2018.5496/2018
A meta-analysis of dietary carbohydrate intake and inflammatory bowel disease risk: evidence from 15 epidemiology studies
DOI: 10.17235/reed.2018.5490/2018
Letter to the Editor
Update of the SEPD position statement on the use of biosimilars for inflammatory bowel disease
DOI: 10.17235/reed.2018.5456/2018
Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: results of a multicenter study after 12 months
DOI: 10.17235/reed.2018.5368/2017
Managing iron deficiency and iron deficiency anemia in inflammatory bowel disease. The results of the “Gestiona hierro-EII” survey
DOI: 10.17235/reed.2018.5354/2017
Using the internet to evaluate the opinion of patients with inflammatory bowel disease with regard to the available information
DOI: 10.17235/reed.2018.5331/2017
Idiopathic portal hypertension with regard to thiopurine treatment
DOI: 10.17235/reed.2018.5256/2017
Assessing medication adherence in inflammatory bowel diseases. A comparison between a self-administered scale and a pharmacy refill index
DOI: 10.17235/reed.2017.5137/2017
The complexity of evaluating and increasing adherence in inflammatory bowel disease
DOI: 10.17235/reed.2017.5143/2017
Serrated polyposis syndrome associated with long-standing inflammatory bowel disease
DOI: 10.17235/reed.2017.5068/2017
Efficacy and safety of vedolizumab as a treatment option for moderate to severe refractory ulcerative colitis in two patients after liver transplant due to primary sclerosing cholangitis
DOI: 10.17235/reed.2017.5024/2017
Colonic diverticulosis and the metabolic syndrome: an association?
DOI: 10.17235/reed.2017.5009/2017
Fecal transplantation as a treatment for Clostridium difficile infection in patients with ulcerative colitis
DOI: 10.17235/reed.2017.4941/2017
Medium to long-term efficacy and safety of oral tacrolimus in moderate to severe steroid refractory ulcerative colitis
DOI: 10.17235/reed.2017.4899/2017
Prevalence, risk factors and response to treatment of extra-intestinal manifestations in patients with inflammatory bowel disease
DOI: 10.17235/reed.2017.4845/2017
Colonic diverticular bleeding. Have we identified the risk factors for massive bleeding yet?
DOI: 10.17235/reed.2017.4821/2017
Fecal microbiota transplantation in recurrent Clostridium difficile infection in a patient with concomitant inflammatory bowel disease
DOI: 10.17235/reed.2017.4819/2016
Diverticulitis of the cecal appendix: a case report
Knowledge of disease and access to a specialist reported by Spanish patients with ulcerative colitis. UC-LIFE survey
DOI: 10.17235/reed.2017.4748/2016
Epidemiology of inflammatory bowel disease in Málaga: incidence rate and follow-up of a cohort diagnosed between 2007-2008
DOI: 10.17235/reed.2017.4708/2016
Ulcerative colitis with gastric and duodenal involvement
DOI: 10.17235/reed.2017.4685/2016
What is the real-life maintenance mesalazine dose in ulcerative colitis?
DOI: 10.17235/reed.2016.4620/2016
The concerns of Spanish patients with inflammatory bowel disease as measured by the RFIPC questionnaire
DOI: 10.17235/reed.2017.4621/2016
Specialist care in the management of inflammatory bowel disease
DOI: 10.17235/reed.2016.4628/2016
Invasive pulmonary aspergillosis in an immunocompromised patient with severe ulcerative colitis
DOI: 10.17235/reed.2017.4564/2016
Mercaptopurine and inflammatory bowel disease: the other thiopurine
DOI: 10.17235/reed.2016.4546/2016
The use of a segmental endoscopic score may improve the prediction of clinical outcomes in acute severe ulcerative colitis
DOI: 10.17235/reed.2016.4470/2016
Previous exposure to biologics and C-reactive protein are associated with the response to tacrolimus in inflammatory bowel disease
DOI: 10.17235/reed.2016.4447/2016
Risk factors for tuberculosis in inflammatory bowel disease: anti-tumor necrosis factor and hospitalization
DOI: 10.17235/reed.2016.4440/2016
How is inflammatory bowel disease managed in Spanish gastroenterology departments? The results of the GESTIONA-EII survey
DOI: 10.17235/reed.2016.4410/2016
Jejunal pseudodiverticulosis. Three cases report
DOI: 10.17235/reed.2017.4403/2016
Therapeutic impact of colon capsule endoscopy with PillCam™ COLON 2 after incomplete standard colonoscopy: a Spanish multicenter study
DOI: 10.17235/reed.2017.4369/2016
Pharmaceutical costs for inflammatory bowel disease units — An issue for department heads? The GESTIONAEII survey
DOI: 10.17235/reed.2016.4192/2016
Meta-analysis of the association between appendiceal orifice inflammation and appendectomy and ulcerative colitis
DOI: 10.17235/reed.2016.4176/2015
All that glitters is not gold. A different cause for an "ulcerative colitis"
Risk factors for severity and recurrence of colonic diverticular bleeding
DOI: 10.17235/reed.2016.4190/2015
Ulcerative colitis in a patient with common variable immunodeficiency: does the treatment differ from the routine?
DOI: 10.17235/reed.2016.4115/2015
Initial experience with golimumab in clinical practice for ulcerative colitis
DOI: 10.17235/reed.2016.4068/2015
Endoluminal calprotectin measurement in assessment of pouchitis and a new index of disease activity: a pilot study
DOI: 10.17235/reed.2016.4066/2015
Mesalamine-induced myopericarditis - A case report
DOI: 10.17235/reed.2016.4016/2015
Idiopathic portal hypertension regarding thiopurine treatment in patients with inflammatory bowel disease
DOI: 10.17235/reed.2015.3954/2015
Contribution of infliximab population pharmacokinetic model for dose optimization in ulcerative colitis patients
DOI: 10.17235/reed.2015.3978/2015
INTENSIFICATION OF MAINTENANCE THERAPY WITH INFLIXIMAB IN ULCERATIVE COLITIS
DOI: 10.17235/reed.2015.3907/2015
Immmunodeficiencies and autoimmune diseases: common variable immunodeficiency and Crohn-like
DOI: 10.17235/reed.2015.3872/2015
FREQUENCY, PREDICTORS, AND CONSEQUENCES OF MAINTENANCE INFLIXIMAB THERAPY INTENSIFICATION IN ULCERATIVE COLITIS
DOI: 10.17235/reed.2015.3804/2015
Impact of the age of diagnosis on the natural history of ulcerative colitis
DOI: 10.17235/reed.2015.3736/2015
Download the citation for this article by clicking on one of the following citation managers:
Received: 16/09/2020
Accepted: 21/09/2020
Online First: 03/12/2020
Published: 07/07/2021
Article Online First time: 78 days
Article editing time: 294 days
Submission and tracking
Access to the information published on the website (www.reed.es) of the Sociedad Española de Patología Digestiva (SEPD), Calle Sancho Dávila, 6, 28028 Madrid, CIF: G28486280, telephone: 914021353, e-mail: sepd@sepd.es, implies acceptance of the following conditions of use:
1. The SEPD published its website in order to make it easier for potential visitors to access information related to its services. The information displayed on this website is made available to users accessing the website, both privately and individually, at no additional cost. The commercialization of access rights is expressly prohibited.
2. It is expressly forbidden to copy or reproduce the information published by means of any electronic medium (web pages, databases, web pages or electronic publications) that allows the dissemination of any information published on this website to multiple users without the prior written consent of the SEPD.
3. Accuracy of information: The SEPD endeavors to display accurate and up-to-date information on its website. However, the SEPD is not responsible for the consequences of reading this information.
4. SEPD is not liable for any damages that the user may cause in connection with access to this website or the use of its contents.
5. Notice to users and/or patients: The information included in www.reed.es is for the exclusive use of healthcare professionals and this will be stated in the registration and access alert.
6. Funding: REED, the official scientific body of the EDPS, shares the same sources of funding as the EDPS, as laid down in Article 22, SECTION VII (ECONOMIC AND DOCUMENTARY SYSTEM) of the EDPS's Statutes.
The website http://www.reed.es may host advertising from third parties that may be considered of interest to the user and in no way a source of budgetary funding for the website. Wherever the word 'Advertising' is displayed, it will be highlighted.
However, advertising that infringes Law 29/2006 on guarantees and rational use of medicines and health products will not be accepted. Likewise, there will be no advertising of any kind in those areas of the website where there may be a conflict of interest.
Advertisers have no rights over their editorial content.
7. Access to restricted areas: In relation to access to restricted areas where the user voluntarily completes the registration form, the EDPS will assign the user a password which will be sent to the e-mail address provided by the user, who must make diligent use of the password and keep it secret. Consequently, the user accepts that he/she is responsible for the correct custody and confidentiality of the password/identifier provided by the EDPS. Furthermore, the user shall not provide access to third parties, either temporarily or permanently, or allow access to third parties.
Consequently, the user is solely responsible for all accesses, contents and actions he/she carries out in connection with his/her user ID and access code, with full indemnity for the EDPS.
On this basis, the user is responsible for immediately informing the EDPS of any factors that allow the misuse of the IDs and/or passwords, such as theft, loss or unauthorized access, in order to cancel them immediately. Until such incidents are reported, SEPD will not be liable for any liability that may arise from the misuse of identifiers or passwords by unauthorized third parties.
The user understands and accepts that he/she is accessing a website with content intended exclusively for medical staff and acknowledges that he/she is a healthcare professional.
Notes of interest to members and visitors to the EDPS website: The data and information contained in all content on these websites are only guidance documents for members and are therefore not legally binding.
8. License for public use of the website: is governed by Spanish law, regardless of the country in which the user accesses the website. Any controversy that may arise in the interpretation of these rules of access will be resolved before the Spanish Courts and Tribunals.
Copyright and Creative Commons POR NC ND: The total or partial reproduction of texts and graphics by any means is prohibited without the express written authorization of the EDPS. To insert these texts, images or news items in the publication or dissemination in any medium of any kind accessible to third parties, the express written consent of the EDPS must be obtained.
The private use of the texts, news and data published on this website is strictly for personal purposes.
The General Data Protection Regulation (Regulation (EU) 2016/679) harmonizes Data Protection legislation across the European Union, increasing the protection of individuals and giving them greater control over their personal data.
At the Spanish Society of Digestive Pathology (SEPD), we have always been concerned about the protection of personal data. We have therefore updated our Privacy Policy in order to bring it into line with the new regulations and to inform you of the changes that affect your rights:
Responsible for the processing of your personal data: SOCIEDAD ESPAÑOLA DE PATOLOGÍA DIGESTIVA (SEPD), CIF: G28486280 and registered office at Calle Sancho Dávila 6, 28028 Madrid.
The data collected by the Sociedad Española de Patología Digestiva (SEPD) are obtained in different ways (website, e-mail, electronic forms or on paper) through its activity as a business association and service provider; these data will become part of an information file for which it is responsible.
Purpose of data collection:
Legitimacy of the processing:
Recipients of the data.
Data subjects:
Everyone can know whether or not the EDPS processes their personal data. They have the right to:
SEPD will cease to process the data, except for legitimate reasons, or for the exercise or defense of possible claims.
Origin of the data: SEPD will obtain personal data directly from the data subject through the following communication channels:
Categories of data:
Sending of commercial communications: In accordance with the LSSI, Law 34/2002, and Law 29/2009, of 30 December, if you do not wish to receive any more commercial communications, please send an e-mail with the word BAJA (unsubscribe) to the following address: sepd@sepd.es.
Security measures: SEPD informs that it has adopted all necessary security measures to prevent theft, alteration or unauthorized access to data, taking into account the state of the art, the costs of implementation, the nature, scope, context and purpose of the processing, as well as the variable risks of probability and severity to the rights and freedoms of individuals, such as in cases of outsourced services, request and ensure that the controller implements appropriate technical and organizational measures to ensure an adequate level of security against existing threats, as stated in art. 32 of the Data Protection Regulation.
Exercise of rights:
Everyone has the right to know whether the EDPS processes his or her personal data. He or she also has the right to:
Access their personal data,
Request the rectification of inaccurate data.
Request deletion when, among other reasons, the data are no longer necessary for the purposes for which they were collected.
Object to the processing of your data, on grounds relating to your particular situation, by requesting that they not be processed by the EDPS.
In certain circumstances, request the restriction of the processing of your data, in which case they will only be kept for the exercise or defense of claims.
Withdraw, at any time, the consent given, without this affecting the lawfulness of the processing that we have carried out prior to such withdrawal.
The interested party may exercise their rights at the following address: Sociedad Española de Patología Digestiva (SEPD), c/ Calle Sancho Dávila, 6 28028 Madrid, or by email to the following address: sepd@sepd.es, any controversy that may arise in the interpretation of these access rules will be resolved before the Spanish Courts and Tribunals.
Remember that whenever you exercise any of the rights set out above, you must accompany your request with a copy of your ID card or equivalent document that allows us to verify your identity.
Likewise, if you are not satisfied with how we have dealt with your rights, you may file a complaint with the Spanish Data Protection Agency, through the website www.aepd.es.
The following table describes in detail the cookies present on the website
The user has also been informed of the cookies used by this website by means of the banner that appears on the home screen during the first browsing visit to this website, in which the user can configure them at their own discretion, requesting their consent and management.
A cookie is a small piece of information, usually a few kilobytes to several megabytes in size, which is stored on your terminal when you visit our website. The cookie is used to remember your preferences and other information about your browsing history of our website.
Cookies can be first-party or third-party cookies. This varies depending on whether the cookies are sent to your terminal from a computer or domain managed by us (own cookies), or are sent from a computer or domain not managed by us (third party cookies). They can remain active from a few minutes to several years, or only during the session.
Cookies can have many purposes and sometimes several are grouped together. In addition, there is a group of technical cookies that are necessary for the proper functioning of website, being mandatory to obtain consent for the rest of the cookies with different purposes. Depending on their purpose we can distinguish,
If you wish, you can also manage cookies through your browser. Most browsers are set by default to accept cookies, but you can change the settings to block, delete and manage some or all cookies if you prefer. Please be aware of the possible changes that can occur when deleting or blocking cookies.
Chrome:
https://support.google.com/chrome/answer/95647?hl=es
Explorer:
https://support.microsoft.com/es-es/topic/eliminar-y-administrar-cookies-168dab11-0753-043d-7c16-ede5947fc64d
Edge:
https://support.microsoft.com/es-es/microsoft-edge/eliminar-las-cookies-en-microsoft-edge-63947406-40ac-c3b8-57b9-2a946a29ae09
Safari:
- Ipad, Iphone, Ipod Touch: https://support.apple.com/es-es/HT201265
- Mac: Preferencias, Panel de privacidad
Firefox:
https://support.mozilla.org/es/kb/Borrar%20cookies